Targeting inflammation in cardiovascular risk
The adverse effects of low-grade systemic inflammation are associated with the development of atherosclerosis, heart failure, obesity-related metabolic disorders, and chronic kidney disease. Because inflammation drives residual cardiovascular risk, Cardiometabolic Health Congress (CMHC) explores current and emerging anti-inflammatory agents in this setting. Inflammation in Atherosclerosis Atherosclerosis is no longer thought to be simply the result […]
